Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 10/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.51 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.51 |
| ▸ | VAT1 | Q99536 | 1/20 | 0.51 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PRNP | P04156 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21839499 | 0.88 | KRAS (0.43) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16636828 | 0.88 | KRAS (0.66) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL26967249 | 0.84 | KRAS (0.47) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29611722 | 0.84 | KIT (0.50) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16636962 | 0.84 | KIT (0.50) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16637205 | 0.84 | ABL1 (0.39) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL19681369 | 0.83 | ACHE (0.44) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL17030840 | 0.83 | MAPT (0.57) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18128592 | 0.82 | KIT (0.42) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL19695793 | 0.81 | HTT (0.49) | KRASEGFRHMOX2CRYZVAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-02-08 | — | — | US | disclosed |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2021-06-24 | — | — | US | disclosed |
| US-10968214-B2 | KRas G12C inhibitors | ELI LILLY AND COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2021051034-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2021-02-23 | — | — | US | disclosed |
| US-10829458-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200115375-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY | 2020-04-16 | — | — | US | disclosed |
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2019-08-06 | — | — | US | disclosed |
| US-10246424-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| EP-3280708-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Araxes Pharma LLC (US) | 2018-02-14 | — | — | EP | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2016164675-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| EP-3055290-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115375-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 57/4885HMOX2 3968/4885 |
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 180/4885HMOX2 4456/4885 |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 247/4885HMOX2 3757/4885 |
| US-10246424-B2 | Substituted quinazoline compounds and methods of use thereof | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 210/4885HMOX2 4526/4885 |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 262/4885HMOX2 4165/4885 |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 210/4885HMOX2 4526/4885 |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 262/4885HMOX2 4165/4885 |
| US-10968214-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 57/4885HMOX2 3968/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 180/4885HMOX2 4456/4885 |
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 365/4885HMOX2 3796/4885 |
| US-10829458-B2 | Substituted quinazoline compounds and methods of use thereof | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 210/4885HMOX2 4526/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 180/4885HMOX2 4456/4885 |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 180/4885HMOX2 4456/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 180/4885HMOX2 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.